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Comorbidities may affect survival and choice of treatment among cancer patients. In fact,
comorbidities have been identified as significant determinants of response to therapy in older
patients with acute myeloid leukemia, breast cancer, head and neck cancer, and lung cancer.
The Charlson comorbidity index and adult comorbidity evaluation-27 are lists of comorbidities
with a weight assigned from 1 to 6 for the former and from 0 to 3 for the latter score, derived
from relative risk estimates of a proportional hazard regression model using clinical data. 
Design and Methods
We retrospectively evaluated the Charlson index and adult comorbidity evaluation-27 score in
a cohort of 125 elderly (> 60 years) patients with chronic phase chronic myeloid leukemia who
received dasatinib after showing resistance or intolerance to imatinib with the aim of establish-
ing associations between comorbidities and the development of pleural effusions or compli-
ance with the drug treatment. 
Results
We found a significant association between the Charlson index as well as the adult comorbidity
evaluation-27 score and the rate of drug reduction or suspension: with regards to the Charlson
index, 49% of score 0 patients had a dose reduction compared to 63% of patients with score
1, 74% of those with score 2 and 100% of patients with score 3-5 (P=0.03); with regards to the
adult comorbidity evaluation-27 score, 45% of patients had score 0-1 and 69% of patients with
score 2-3 had a dose reduction. Of the 65 patients with Charlson score 0, 29% had at least one
suspension of treatment (79% for hematologic and 21% for non-hematologic toxicity), com-
pared to 46% of patients with score 1 (37% for hematologic and 69% for non-hematologic tox-
icity), 58% of patients with score 2 (36% for hematologic and 64% for non-hematologic toxi-
city) and 100% of patients with score 3 or 4 (all patients for both types of toxicity). High adult
comorbidity index-27 scores identified patients at high risk of grade 3/4 hematologic toxicity.
Forty-one patients (32.8%) experienced pleural effusion during treatment: the highest scores
for both indices were associated with an increased risk of pleural effusions. 
Conclusions
In elderly patients with chronic myeloid leukemia treated with dasatinib, the rate of drug
reduction or suspension and the incidence of pleural effusions seem to be associated with the
presence of comorbidities: stratification according to the Charlson index and adult comorbidity
evaluation-27 score before dasatinib therapy may enable the identification of patients at risk of
major toxicities.
Key words: chronic myeloid leukemia, dasatinib, Charlson comorbidity index, adult comor-
bidity evaluation 27 (ACE-27).
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Introduction
Despite the beneficial effect of imatinib treatment in
chronic myeloid leukemia (CML), some patients develop
resistance and/or intolerance to this drug and need to
switch to second-generation tyrosine kinase inhibitors
such as nilotinib or dasatinib.1,2 Dasatinib is an oral dual
tyrosine kinase inhibitor active against abl and Src-family
kinases; it inhibits BCR–ABL1 with a 50% inhibitory con-
centration (IC50) of less than 1 nmol/L and its structure is
based on a different chemical scaffold to that of imatinib
with a 325-fold greater potency.3
Pleural/pericardial effusions are possible complications
during treatment with dasatinib and are usually managed
by reducing the dose of the drug administered or discon-
tinuing the drug completely.4 Changing the dasatinib regi-
men from 70 mg twice daily to 100 mg once daily reduces
the risk of this complication.5 Several factors have been
indicated to predispose to pleural effusions, such as a pre-
vious history of cardiac disease or auto-immune disorders,
a previous skin rash as an adverse event occurring during
imatinib treatment, hypertension, hypercholesterolemia,
advanced disease phase, twice daily dosing regimen, and
high dose of the drug.6,7
Comorbidity, as defined by Feinstein,8 is any distinct
additional clinical entity that pre-exists or occurs during
the clinical course of a patient with a primary disease.
Comorbidities may affect survival and choice of treatment
among cancer patients: in fact they have been identified as
significant determinants of response to therapy in older
patients with acute myeloid leukemia, female breast can-
cer, head and neck cancer or lung cancer.9,10 The Charlson
comorbidity index (CCI) is a list of 19 comorbid condi-
tions: each condition has a weight assigned from 1 to 6,
which was derived from relative risk estimates of a pro-
portional hazard regression model using clinical data. The
adult comorbidity evaluation-27 (ACE27) is a new 27-item
comorbidity index for patients with cancer.9 The ACE27
was developed through modification of the Kaplan-
Feinstein Comorbidity Index. ACE27 includes comorbid
conditions of various organ systems such as cardiovascu-
lar, respiratory, gastrointestinal, renal, endocrine, neuro-
logical, psychiatric, rheumatological, and immunological
systems, as well as malignancy, substance abuse, and
body weight. Each category has three grades (1, mild; 2,
moderate; and 3, severe), with the overall comorbidity
score defined according to the highest ranked single ail-
ment. Two or more grade 2 ailments occurring in different
organ systems result in a grade 3 assignment. ACE27
grades were listed as 0, 1, 2 or 3 in the hospital informa-
tion system. 
There are only limited data in the literature on the role
of comorbidities in CML patients, and the data are essen-
tially from patients who were candidates for allogeneic
bone marrow transplantation.11 The aim of our study was
to establish the impact of comorbidities in the setting of
elderly CML patients switched to dasatinib following
resistance to imatinib, and to assess their possible role in
the development of toxicities. 
Design and Methods
The present study included 125 patients aged over 60 years old
with CML in chronic phase treated in 21 Italian Centers, who
received dasatinib after being resistant or intolerant to imatinib.
Participating centers were asked to send data on all consecutive
chronic phase CML patients who fulfilled the following inclusion
criteria, irrespective of response or median time on treatment: (i)
age greater than 60 years; (ii) in chronic phase at the time of start-
ing dasatinib. No exclusion criteria were considered. Patients were
treated with dasatinib given for compassionate use or prescribed,
from 2007, after imatinib resistance or intolerance. Baseline data
(sex, age, Sokal risk, imatinib dose, reason for switching to dasa-
tinib, other therapy, starting dose of dasatinib) were recorded at
the time of both imatinib and dasatinib treatment: during this lat-
ter treatment we also recorded the dosage, any side effects and
grades of toxicity, days of interruptions, and reasons for discontin-
uing the drug. Responses to standard-dose imatinib were defined
according to European LeukemiaNet recommendations.12
Intolerance to imatinib was defined as the occurrence of severe
or moderate but persistent or recurrent hematologic or extra-
hematologic toxicity during imatinib treatment, requiring perma-
nent drug discontinuation. Hematologic and extra-hematologic
toxicities were graded according to the World Health
Organization (WHO) scale, such that severe toxicity was consid-
ered grade 3-4 on the WHO scale and moderate toxicity as grade
2 on the WHO scale.
Comorbidities were registered in all patients at the time of diag-
nosis by medical staff, before any therapeutic intervention. On the
basis of the information collected we retrospectively calculated
the modified CCI and ACE27 (Table 1).9 Analyses were conducted
of the impact of stratification according to the CCI and the hema-
tologic and non-hematologic toxicities experienced during dasa-
tinib treatment. A complete ACE27 data form is available on
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Table 1. Charlson comorbidity index.
Score Condition
1
Myocardial infarction (history, not ECG changes only)
Congestive heart failure
Peripheral vascular disease (includes aortic aneurysm ≥ 6 cm)





Mild liver disease (without portal hypertension, includes 
chronic hepatitis)
Diabetes without end-organ damage (excludes diet-controlled alone)
2
Hemiplegia
Moderate or severe renal disease
Diabetes with end-organ damage (retinopathy, neuropathy, 
nephropathy, or brittle diabetes)
Tumor without metastases (exclude if >5 years from diagnosis)
Leukemia (acute or chronic)
Lymphoma
3
Moderate or severe liver disease
6
Metastatic solid tumor
AIDS (not just HIV positive)
TIA: transient ischemic attacks; HIV: human immunodeficiency virus.
http://oto.wustl.edu/clinepi/calc.html (Clinical Outcomes Research
Office’s Website). This study was approved by the Ethics Board
and all patients provided informed consent according to institu-
tional guidelines.
Statistical analyses were carried out using the SPSS software
package. In particular, responses and frequency of toxicities were
compared using a χ2 or Fisher’s exact test. With a Cochran-
Armitage test of trend we assessed the presence of an association
between variables with several categories. P values less than 0.05
were considered statistically significant.
Results
The patients’ clinical features are shown in Table 2.
There were 63 males and 62 females; the Sokal risk score
at diagnosis was low in 34 patients, intermediate in 49,
high in 19 and not evaluable in 25. The median age at the
time of starting dasatinib therapy was 69.9 years
(interquartile range, 65.4–74.4), the median interval from
diagnosis to dasatinib therapy was 75.8 months
(interquartile range, 39.1–115.9); 57/125 patients (45.6%)
had received interferon-based therapy before imatinib. As
regards imatinib treatment, all but nine patients had ini-
tially received the 400 mg daily standard dosage and in
58/125 patients (46.4%) the dosage was increased to
600–800 mg/day; overall, the median period of imatinib
treatment was 46.6 months (interquartile range,
21.8–61.8). Thirteen patients were considered as intoler-
ant to imatinib treatment and 112 as resistant to this ther-
apy. The starting dosage of dasatinib was 140 mg in 52
patients, 100 mg in 56 patients and less than 100 mg in the
remaining 17 patients. 
Table 3 shows the correlations between CCI stratifica-
tion and toxicity and adjustment of dasatinib dose. With
regards to the CCI stratification, a score of 0 was assigned
to 65 patients, whereas a score of 1 or more was assigned
to 60 patients (35 patients, score 1; 19 patients, score 2; 5
patients, score 3; 1 patient, score 4). We found a significant
association between CCI score and the rate of drug dose
reduction or suspension: during dasatinib treatment 49%
of score 0 patients had a dose reduction compared to 63%
of patients with score 1, 74% of patients with score 2 and
100% of patients with score 3 or 4 (P=0.0001, Table 3). Of
the 65 patients with score 0, 29% had at least one suspen-
sion (79% for hematologic and 21% for non-hematologic
toxicity), compared to 46% of patients with score 1 (37%
for hematologic and 69% for non-hematologic toxicity),
58% of patients with score 2 (36% for hematologic and
64% for non-hematologic toxicity) and 100% of patients
with score 3 or 4 (all patients for both types of toxicity)
(P=0.0002). ACE27 stratification identified high frequen-
cies of reductions and temporary suspensions in patients
with score 2 or 3.
Both the CCI and ACE27 stratification were able to
identify patients with a high risk of developing hemato-
logic toxicity: grade 3/4 neutropenia and thrombocytope-
nia most frequently occurred in patients with an overall
CCI score of 2-4 and a grade 2 or higher ACE27 score
(Table 4). 
Table 5 shows the correlations between CCI and ACE27
stratification and the incidence and grade of pleural effu-
sions. During dasatinib treatment, 41/125 patients (32.8%)
presented with a pleural effusion, which was of grade 2 in
31 patients and of grade 3 or 4 in ten patients (24.4% of
the 41 patients with pleural effusion and 8% of the entire
cohort of patients), according to the WHO scale; in 11/41
patients (26.8%), there was a concomitant pericardial effu-
sion. In addition, pleural effusion was recurrent in 19/41
patients (46.4%). The median time from starting dasatinib
treatment to the occurrence of the first pleural effusion
was 10.4 months (interquartile range, 2.2 – 18.1). Among
the 41 patients with a pleural effusion, eight (19.5%) did
not require interruption of dasatinib while 33 (80.5%) dis-
continued therapy; however, dasatinib was successfully
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Median age (range) 69.9 (65.4-74.4)





Median time of treatment with imatinib 46.6 (21.8-61.8)
(months, range)






Reason for switching to dasatinib
Primary resistance to imatinib 60
Loss of complete cytogenetic response 48
Loss of major molecular response 4
Intolerance to imatinib 13
Nilotinib pre-dasatinib 12
Starting dose of dasatinib 
140 mg 52
100 mg 56
< 100 mg 17
Table 3. Correlations between CCI and ACE27 stratification and dasa-
tinib dose adjustment
Reduction P Temporary P Total
n. (%) suspension n. of patients





0 (65 pts) 32 (49%) 0.0001 19 (29%) 0.0002 32 (49%)
1 (35 pts) 22 (63%) 16 (46%) 22 (63%)
2 (19 pts) 14 (74%) 11 (58%) 14 (74%)
3-4 (6 pts) 6 (100%) 6 (100%) 6 (100%)
ACE27 score
0 (43 pts) 19 (39%) 0.02 10 (10%) 0.0001 19 (39%)
1 (14 pts) 2 (4%) 3 (21%) 3 (21%)
2 (57 pts) 39 (68%) 23 (40%) 39 (68%)
3 (13 pts) 8 (61%) 10 (77%) 10 (77%)
restarted in 28/33 patients (84.8%) after a median period
of 20 days (interquartile range, 15–38) and, overall, only
five patients (12.1% of the 41 patients with a pleural effu-
sion and 4% of the entire cohort of patients) required per-
manent discontinuation of dasatinib. 
CCI stratification applied to the 41 patients (32.8%)
who experienced pleural effusion during treatment
revealed that this complication occurred in 17 (26%) of the
65 patients with score 0, 13 (37%) of the 35 patients with
score 1, in 8 (42%) of the 19 patients with score 2 and in
3 (50%) of the 6 patients with score 3 or 4. More pleural
effusions occurred in patients who had a score of 1 or
more but received a higher dose of dasatinib (140 mg).
The severity of pleural effusions showed the same corre-
lation: a grade 3 effusion was detected only in patients
with a CCI score of greater than 2. Likewise, higher fre-
quencies of pleural effusions were observed among
patients with an ACE27 score of 2 or 3 and a similar cor-
relation was seen regarding the intensity and severity of
effusions. There were no differences among patients with
or without pleural effusions as concerns response rate and
overall survival (data not shown). 
Discussion
The choice of second-line therapy of CML in the era of
tyrosine kinase inhibitors is currently based on the type of
mutation that developed during imatinib treatment and on
comorbidities associated with the disease, because of the
different side effects of the various drugs.14 Pleural effusion
is a rather frequent complication of dasatinib therapy; it is
usually mild to moderate and is associated with several
risk factors, such as advanced disease phases, a twice-daily
dosing schedule, a daily dose equal to or higher than 140
mg, and concomitant or previous cardiac disease.15 The
pathogenesis is likely multi-factorial, and is possibly due
to tyrosine-kinase inhibition or immune-mediated effects
involving other tyrosine kinases (TEC or BTK of lympho-
cyte B and T signaling).7 The management of this side
effect includes therapy interruption, drug dose reduction,
steroids and diuretics and, only in a few severe instances,
therapeutic thoracentesis.6,7,15 Data from a phase III trial
showed a slight increase of the incidence of this side effect
over time, but not of grade 4 cases, after a follow-up of 3
years.5 With adequate management and monitoring of
patients with predisposing factors, the majority of individ-
uals can continue therapy with the drug, even in the pres-
ence of this complication.
Until now, no published studies performed a complete
analysis of concomitant diseases or medications associat-
ed with dasatinib-induced pleural effusion, although
Porkka et al. reported that older age (>66 years) is the most
important negative prognostic factor, based on the results
of an optimization phase III trial of dasatinib in patients
resistant/intolerant to imatinib.4 The median age of
patients enrolled in the 100 mg once daily arm of this trial
was 56 years. The incidence of pleural effusions of all
grades was 14% compared to 25% in the 70 mg twice
daily arm and the last follow-up confirmed a slight
increase of all grades and the absence of grade 4. In our
series of elderly patients, the overall rate of pleural effu-
sions was higher than that in other published studies,
probably because we did not use exclusion criteria for
observation of this group of patients. Recently, Khoury et
al. reported the role of age in patients treated with front-
line dasatinib 100 mg once daily: no age-related differ-
ences were found in efficacy, whereas the safety profile of
the drug differed according to the age of the patients, with
the fluid retention rate being 35% in patients aged over 65
years compared to 13% in patients aged under 46 years
old.16 The effect of  dasatinib combined with concomitant
medications was recently examined in a sub-analysis of
patients who received front-line dasatinib: the rate of fluid
retention in patients who received dasatinib alone or asso-
ciated with one to three of four or more concomitant med-
ications was 9%, 23% and 24%, respectively. The pleural
effusion rate was 1% in patients who took dasatinib alone
and 13% in patients who took dasatinib in association
with concomitant drugs.17
Comorbidities and poor performance status influence
the prognosis of patients affected by cancers.9,10
Comorbidities may influence clinical decision-making con-
cerning treatment; in studies on various types of cancer,
comorbidities have been shown not only to affect cancer
risk, but also to affect cancer survival by limiting treatment
choices, especially in the subset of elderly patients.9 An
accurate evaluation of extra-hematologic comorbidities
must be part of the prognostic assessment of patients with
CML, especially those who need treatment with a second-
generation tyrosine kinase inhibitor. At present the choice
of a second-line tyrosine kinase inhibitor can be based on
an individual’s mutational profile and comorbidities. 
In our experience, the application of two different
comorbidity scores, i.e. the CCI and ACE27, might be of
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Table 4. ACE27 and CCI stratification and hematologic toxicity (neu-
tropenia and/or thrombocytopenia).
Score (n. of pts) N. of patients who N. of patients who P*
experienced toxicity experienced toxicity
grade 1-2 (%) grade 3-4 (%)
CCI score 0 (65 pts) 10 (23%) 51 (78%) 0.001
CCI score 1 (35 pts) 11 (31%) 15 (43%) ns
CCI score 2 (19 pts) - 7 (36%) 0.02
CCI score 3-4 (6 pts) - 6 (100%) 0.001
ACE27 score 0 (43 pts) 18 (41%) 11 (25%) ns
ACE27 score 1 (14 pts) 43 (32%) 2 (14%) ns
ACE27 score 2 (57 pts) 10 (17%) 22 (39%) 0.001
ACE27 score 3 (13 pts) 1 (1%) 2 (15%) 0.003
*P refers to comparison between two groups of patients
Table 5. Correlations between CCI and ACE27 stratification and inci-
dence and grade of pleural effusions.
Score and n. of pts           Pleural effusion (%)             Grade of toxicity
CCI score 0 (65 pts)                      17 (26%)                           100% grade 1-2
CCI score 1 (35 pts)                      13 (37%)                           100% grade 1-2
CCI score 2 (19 pts)                       8 (42%)                             80% grade 1-2
                                                                                                             20% grade 3
CCI score 3-4 (6 pts)                       3 (50%)                              100% grade 3
ACE27 score 0-1  (53 pts)              13 (24%)                           100% grade 1-2
ACE 27 score 2-3  (72 pts)             28 (39%)                            90% grade 1-2
                                                                                                             10% grade 3
                                                                                                             10% grade 3
help in identifying patients at higher risk of the develop-
ment of pleural effusions; such patients need close moni-
toring of adverse events during dasatinib treatment. In
fact, we found a correlation between the CCI and ACE27
stratifications and the incidence of pleural effusion, with
effusions being more frequent among patients with a
score of 2 or more. 
Both the CCI and ACE27 stratifications were able to
identify patients at high risk of hematologic toxicity and
decreased compliance: the higher the comorbidity score,
the higher the risk of developing toxicity and consequent
requirement for temporary drug suspension. The results
of our study showed that the evaluation of comorbidities
may help to identify patients at higher risk of scarce
compliance due to toxicity: these findings do not imply
that the drug cannot be used in this setting of patients
nor that the patients cannot be protected from develop-
ing pleural effusions, based on the evaluation of comor-
bidities. Comorbidities deserve more attention during
treatment in order to adjust the dose appropriately, peri-
odically monitor cardiac safety, optimize blood pressure
and serum cholesterol levels and promptly evaluate chest
X-rays at the first appearance of symptoms of effusions,
such as a dry cough or dyspnea. 
In conclusion, evaluation of comorbidities in elderly
CML patients before treatment with dasatinib could be
useful to identify subjects at higher risk of developing
complications and to tailor treatment.
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